Study the effect of Canagliflozin in patients of type 2 diabetes mellitus inadequately controlled on maximum dose of three oral hypoglycemic agents
Keywords:
diabetes, hypoglycemic agents, metforminAbstract
Metformin is the first- line pharmacotherapeutic agent implemented after life style modification to achieve the desired glycemic levels in patient with T2DM. [4] However, Metformin alone in many patients fail to maintain the desired glycemic levels in long term and they will require additional combination therapies.[5] Even though effective initially , agents included in the class of sulfonylurea has common side effects like hypoglycemia and weight gain.[6] It is also observed that drugs acting on pancreatic β cells will cause early exhaustion of β cells and the use of agents that utilize the insulin dependent pathways. After the analysis of data collected at the end of the study it was found that there was a significant reduction in fasting and post prandial blood sugar levels, HbA1c value and body weight. Along with these benefits few adverse effect including simple urinary tract infection, genital mycotic infection were recorded, these ADRs were mild and symptoms subsided after routine treatment.
Downloads
References
Power A. Harrison's principal of internal medicine. 16th ed. USA: McGraw-Hill Companies; 2005.
Defronzo, R. A. (2010). Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009. Diabetologia, 53, 1270–1287
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, et al. (2012). Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 35, 1364–1379.
Centers for Disease Control and Prevention National diabetes statistics report: estimates of diabetes and its burden in the United States. 2014. [Last accessed September 23, 2018]. Available at:http://www.cdc.gov/diabetes/pubs/statsreport14/national- diabetes-report-web.pdf
Prevalence of diabetes and prediabetes and their risk factors among Bangladeshi adults: a nationwide survey Shamima Akter,a M Mizanur Rahman,b Sarah Krull Abeb & Papia Sultanac
Gale, Jason (November 7, 2010). "India's Diabetes Epidemic Cuts Down Millions Who Escape Poverty". Bloomberg. Retrieved 8 June 2012.
Hermansen K, Mortensen LS. (2007) 'Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.', drug safety , 30(12)(1127), pp. 42.
American Diabetes Association Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(suppl):S14–S80. http://dx.doi.org/10.2337/dc14-S014. [PubMed]
Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement–executivesummary. EndocrPract.2013;19(3):53657. http://dx.doi.org/10.4158/EP13176.CS. [PMC free article] [PubMed]
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care.2009;32(1):193–203. http://dx.doi.org/10.2337/dc08-9025. [PMC free article] [PubMed]
InzucchiSE,BergenstalRM,BuseJB,etal. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577–96
Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427– 43
Bodmer M, Meier C, Krähenb€uhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case- controlanalysis.DiabetesCare2008; 31:2086–2091
Ng JM, Mellor DD, Masson EA, Allan BJ. Sulphonyurea as a cause of severe hypoglycaemia in the community. Prim Care Diabetes 2010;4:61–63
Campbell RK. Fate of the beta-cell in the pathophysiology of type 2 diabetes. J Am Pharm Assoc (2003) 2009;49(Suppl. 1): S10–S15
Morgan CL, Jenkins-Jones S, Evans M, Barnett AH, Poole CD, Currie CJ. Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. Diabetes Obes Metab 2012;14:424–32
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the
initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203. doi: 10.2337/dc08-9025. [PMC free article] [PubMed][Cross Ref]
Logtenberg SJ, Kleefstra N, Ubink-Veltmaat LJ, Houweling ST, Bilo HJ. Intensification of therapy and no increase in body mass index with longer disease duration in type 2 diabetes mellitus(ZODIAC-5) FamPract. 2007;24:529-531. doi:10.1093/fampra/cmm064. [PubMed]
United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1483–88, 1995
Korytkowski M: When oral agents fail: practical barriers to starting insulin. Int J ObesRelatMetabDisord26:S18 –S24,2002
Okazaki K, Goto M, Yamamoto T, Tsujii S, Ishii H: Barriers and facilitators in relation to starting insulin therapy in type 2 diabetes (Abstract). Diabetes 48 (Suppl.1):A319
Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988– 2010. Diabetes Care. 2013;36(8):2271–9.http://dx.doi.org/10.2337/dc12-2258. [PMC free article] [PubMed]
Pfister M, Whaley JM, Zhang L, List JF. Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus. Clin Pharmacol Ther. 2011;89(4):6215. http://dx.doi.org/10.1038/clpt.2011.16. [PubMed]
DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia. Diabetes ObesMetab. 2012;14:5–14. [PubMed]
Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest. 1971;28:101–9.[PubMed]
Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: Role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272–7. [PubMed]
Tahrani A, Bailey C, Del Prato S, Barnett AH. Management of type 2 diabetes: New and future developments in treatment. Lancet. 2011;378:182–97. [PubMed]
Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M. Long-term treatment with sergliflozinetabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol. 2009;618:98–104. [PubMed]
Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. ClinPharmacolTher. 2009;85:520–6. [PubMed]
Nyandra, M., Kartiko, B.H., Susanto, P.C., Supriyati, A., Suryasa, W. (2018). Education and training improve quality of life and decrease depression score in elderly population. Eurasian Journal of Analytical Chemistry, 13(2), 371-377.
Nyandra, M., Suryasa, W. (2018). Holistic approach to help sexual dysfunction. Eurasian Journal of Analytical Chemistry, 13(3), pp. 207–212.
Amir, . F., Suhron, M., & Sulaihah, S. (2021). Family care model development in treating schizophrenia patients that have self-deficit nursing based system: Structural equation modeling analysis. International Journal of Health & Medical Sciences, 5(1), 7-14. https://doi.org/10.21744/ijhms.v5n1.1808
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
